| # | Title | Journal | Year | Citations |
|---|
| 1 | EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update | Annals of the Rheumatic Diseases | 2017 | 3,366 |
| 2 | Rheumatoid arthritis | Lancet, The | 2010 | 2,712 |
| 3 | Genetics of rheumatoid arthritis contributes to biology and drug discovery | Nature | 2014 | 1,974 |
| 4 | EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update | Annals of the Rheumatic Diseases | 2020 | 1,860 |
| 5 | EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update | Annals of the Rheumatic Diseases | 2014 | 1,688 |
| 6 | The PREMIER study: A multicenter, randomized, double‐blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment | Arthritis and Rheumatism | 2006 | 1,634 |
| 7 | 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis | Annals of the Rheumatic Diseases | 2017 | 1,220 |
| 8 | Genome-wide association study meta-analysis identifies seven new rheumatoid arthritis risk loci | Nature Genetics | 2010 | 1,132 |
| 9 | Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force | Annals of the Rheumatic Diseases | 2016 | 1,114 |
| 10 | Transient expression of FOXP3 in human activated nonregulatory CD4+ T cells | European Journal of Immunology | 2007 | 912 |
| 11 | 2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis | Annals of the Rheumatic Diseases | 2011 | 831 |
| 12 | Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis | Annals of the Rheumatic Diseases | 2009 | 772 |
| 13 | Guidelines for the use of flow cytometry and cell sorting in immunological studies (second edition) | European Journal of Immunology | 2019 | 766 |
| 14 | EULAR recommendations for the use of imaging in large vessel vasculitis in clinical practice | Annals of the Rheumatic Diseases | 2018 | 753 |
| 15 | European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update | Annals of the Rheumatic Diseases | 2016 | 743 |
| 16 | Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial | Lancet, The | 2015 | 722 |
| 17 | Defining active sacroiliitis on magnetic resonance imaging (MRI) for classification of axial spondyloarthritis: a consensual approach by the ASAS/OMERACT MRI group | Annals of the Rheumatic Diseases | 2009 | 719 |
| 18 | Dense genotyping identifies and localizes multiple common and rare variant association signals in celiac disease | Nature Genetics | 2011 | 682 |
| 19 | EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics | Annals of the Rheumatic Diseases | 2008 | 645 |
| 20 | How to diagnose rheumatoid arthritis early: A prediction model for persistent (erosive) arthritis | Arthritis and Rheumatism | 2002 | 635 |
| 21 | EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task force of the EULAR standing committee for clinical affairs | Annals of the Rheumatic Diseases | 2010 | 578 |
| 22 | Autologous Hematopoietic Stem Cell Transplantation vs Intravenous Pulse Cyclophosphamide in Diffuse Cutaneous Systemic Sclerosis | JAMA - Journal of the American Medical Association | 2014 | 566 |
| 23 | Autoantibodies to cyclic citrullinated peptides predict progression to rheumatoid arthritis in patients with undifferentiated arthritis: A prospective cohort study | Arthritis and Rheumatism | 2004 | 562 |
| 24 | Cytokine gene polymorphism in human disease: on-line databases | Genes and Immunity | 1999 | 560 |
| 25 | High-density genetic mapping identifies new susceptibility loci for rheumatoid arthritis | Nature Genetics | 2012 | 558 |
| 26 | The transcriptional landscape of age in human peripheral blood | Nature Communications | 2015 | 533 |
| 27 | Early versus delayed treatment in patients with recent-onset rheumatoid arthritis: comparison of two cohorts who received different treatment strategies | American Journal of Medicine | 2001 | 513 |
| 28 | Synovial inflammation, immune cells and their cytokines in osteoarthritis: a review | Osteoarthritis and Cartilage | 2012 | 506 |
| 29 | EULAR recommendations for the use of imaging of the joints in the clinical management of rheumatoid arthritis | Annals of the Rheumatic Diseases | 2013 | 504 |
| 30 | ASDAS, a highly discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis | Annals of the Rheumatic Diseases | 2009 | 491 |
| 31 | Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force | Annals of the Rheumatic Diseases | 2018 | 484 |
| 32 | Common variants at CD40 and other loci confer risk of rheumatoid arthritis | Nature Genetics | 2008 | 476 |
| 33 | Autoantibodies recognizing carbamylated proteins are present in sera of patients with rheumatoid arthritis and predict joint damage | Proceedings of the National Academy of Sciences of the United States of America | 2011 | 464 |
| 34 | Radiographic findings following two years of infliximab therapy in patients with ankylosing spondylitis | Arthritis and Rheumatism | 2008 | 461 |
| 35 | Safety of synthetic and biological DMARDs: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis | Annals of the Rheumatic Diseases | 2014 | 456 |
| 36 | Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1 | Annals of the Rheumatic Diseases | 2017 | 454 |
| 37 | Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results of a randomised placebo-controlled trial (ABILITY-1) | Annals of the Rheumatic Diseases | 2013 | 449 |
| 38 | Discrete Cleavage Motifs of Constitutive and Immunoproteasomes Revealed by Quantitative Analysis of Cleavage Products | Journal of Experimental Medicine | 2001 | 427 |
| 39 | Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial | Annals of the Rheumatic Diseases | 2009 | 424 |
| 40 | Multinational evidence-based recommendations for the use of methotrexate in rheumatic disorders with a focus on rheumatoid arthritis: integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in the 3E Initiative | Annals of the Rheumatic Diseases | 2009 | 404 |
| 41 | EULAR recommendations for the use of imaging in the diagnosis and management of spondyloarthritis in clinical practice | Annals of the Rheumatic Diseases | 2015 | 402 |
| 42 | Antibodies to citrullinated proteins and differences in clinical progression of rheumatoid arthritis | Arthritis Research and Therapy | 2005 | 400 |
| 43 | Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force | Annals of the Rheumatic Diseases | 2014 | 397 |
| 44 | Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis | Annals of the Rheumatic Diseases | 2011 | 394 |
| 45 | Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind randomised placebo-controlled study (RAPID-PsA) | Annals of the Rheumatic Diseases | 2014 | 393 |
| 46 | 2016 update of the EULAR recommendations for the management of early arthritis | Annals of the Rheumatic Diseases | 2017 | 393 |
| 47 | Comparison of Treatment Strategies in Early Rheumatoid Arthritis | Annals of Internal Medicine | 2007 | 390 |
| 48 | Defining active sacroiliitis on MRI for classification of axial spondyloarthritis: update by the ASAS MRI working group | Annals of the Rheumatic Diseases | 2016 | 383 |
| 49 | 2010 Update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis | Annals of the Rheumatic Diseases | 2011 | 365 |
| 50 | The etiology of rheumatoid arthritis | Journal of Autoimmunity | 2020 | 362 |
